Clinical trials: NAFLD Cirrhosis
Non-Alcoholic Fatty Liver Disease
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis
Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.
- Trial name
- NCT04142749
- Testing
- Oltipraz
- Where
- 21 sites in South Korea
- Volunteers
- 146 people
- Sponsor
- PharmaKing
Fatty Liver, Cirrhosis
Development of a Breath Test for Monitoring Patients With Liver Disease
The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.
- Trial name
- NCT00244569
- Testing
- 13C-Methacetin, Breath ID Machine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Virginia Commonwealth University
Non Alcoholic Steatohepatitis, Hyperuricemia
Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
This study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis.
- Trial name
- NCT05574036
- Testing
- Febuxostat 80 MG Oral Tablet, vit E
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Liver Fibrosis, Liver Steatosis
NAFLD and Liver Fibrosis in Obese Adolescents
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the…
- Conditions
- Liver Fibrosis, Liver Steatosis, Weight Loss
- Trial name
- NAFLD (NCT04561804)
- Testing
- laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Non-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis.
- Trial name
- NCT05384652
- Where
- Hong Kong
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Nonalcoholic Steatohepatitis
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02510599
- Testing
- solithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melinta Therapeutics, Inc.
Fatty Liver, Liver Fibrosis
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic…
- Conditions
- Fatty Liver, Liver Fibrosis, Obesity, Metabolic Syndrome
- Trial name
- NCT01934777
- Testing
- Docosahexaenoic Acid plus Vitamin E plus choline
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Type2 Diabetes, Fatty Liver, Nonalcoholic
Mechanism of Serum PRL in the Development of MAFLD
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently.
- Conditions
- Type2 Diabetes, Fatty Liver, Nonalcoholic, Liver Fibrosis
- Trial name
- NCT05525884
- Testing
- non-invasive method, Fibroscan
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Shen Qu
Liver Fibrosis, Liver Cirrhosis
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness
Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.
- Conditions
- Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC
- Trial name
- NCT07716384
- Testing
- Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan)
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Non-Alcoholic Fatty Liver Disease
Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation
Patients with NAFLD indicated for ursodeoxycholic acid treatment ("by SPC: cholestatic hepatitis") will be offered an observational study. Examinations will be performed before the treatment and after 6month period.
- Trial name
- URSO (NCT05256979)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- General University Hospital, Prague
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
The investigators use machine learning capabilities on massive electronic health records for the purpose of developing a model that prioritizes individuals at high risk of progressing to liver cirrhosis, and validating it with…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05218538
- Testing
- Fibroscan (non interventional)
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- HaEmek Medical Center, Israel
NAFLD, Liver Cirrhosis
Risk Factors for Advanced Fibrosis Among FLD Patients
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication.
- Conditions
- NAFLD, Liver Cirrhosis, Diabetes Mellitus, Type 2
- Trial name
- FLD_FU_HUS (NCT05971082)
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Non Alcoholic Fatty Liver Disease
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
The purpose of this randomized clinical trial is to evaluate the utility of noninvasive markers for the detection of advanced fibrosis in patients newly diagnosed with Non-alcoholic Fatty Liver Disease (NAFLD) by ultrasound.
- Trial name
- NCT01874249
- Testing
- Electronic detailed information, NAFLD Score, Transient elastography
- Where
- Mexico
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Fundación Clínica Médica Sur
Non-alcoholic Steatohepatitis (NASH)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis
- Trial name
- NCT04607655
- Testing
- GB1211
- Sponsor
- Galecto Biotech AB
Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis
Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS)
Objective of the study Our working hypothesis is that platelets activated by gut-derived metabolites dock in the liver of NAFLD patients and amplify the inflammatory state by releasing pro-inflammatory cytokines/chemokines, which…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Control Condition
- Trial name
- NCT06623084
- Testing
- Platelets characterization
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Stefania Basili
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis
In a retrospective study, 200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fatty liver fibrosis have been identified for pathological diagnosis of liver histology and exclusion of other liver…
- Trial name
- NCT03842748
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD)
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe…
- Conditions
- Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 1 (NCT03486899)
- Testing
- BMS-986036
- Where
- 89 sites in United States, Japan
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb